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Abstract
Background and Aims: Celiac disease is a permanent intolerance to gluten prolamins from wheat, barley, rye and, in some
patients, oats. Partially digested gluten peptides produced in the digestive tract cause inflammation of the small intestine.
High throughput, immune-based assays using monoclonal antibodies specific for these immunotoxic peptides would
facilitate their detection in food and enable monitoring of their enzymatic detoxification. Two monoclonal antibodies, G12
and A1, were developed against a highly immunotoxic 33-mer peptide. The potential of each antibody for quantifying food
toxicity for celiac patients was studied.
Methods: Epitope preferences of G12 and A1 antibodies were determined by ELISA with gluten-derived peptide variants of
recombinant, synthetic or enzymatic origin.
Results: The recognition sequences of G12 and A1 antibodies were hexameric and heptameric epitopes, respectively.
Although G12 affinity for the 33-mer was superior to A1, the sensitivity for gluten detection was higher for A1. This
observation correlated to the higher number of A1 epitopes found in prolamins than G12 epitopes. Activation of T cell from
gluten digested by glutenases decreased equivalently to the detection of intact peptides by A1 antibody. Peptide
recognition of A1 included gliadin peptides involved in the both the adaptive and innate immunological response in celiac
disease.
Conclusions: The sensitivity and epitope preferences of the A1 antibody resulted to be useful to detect gluten relevant
peptides to infer the potential toxicity of food for celiac patients as well as to monitor peptide modifications by
transglutaminase 2 or glutenases.
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Introduction
Celiac disease (CD) is a common autoimmune disorder that has
genetic, environmental, and immunological components. Though
under-diagnosed, it is one of the most prevalent chronic
gastrointestinal diseases in humans, and exhibits unusually large
clinical, histological, immunological, and genetic heterogeneity
[1,2]. The clinical spectrum of CD has been expanded in recent
years, with the identification of asymptomatic patients, patients
with minimal symptoms (the most difficult to detect), and patients
with extra-intestinal symptoms [2–5]. Regardless of symptomatic
presentation, active disease in virtually all CD patients relies on
dietary exposure to a common environmental antigen, gluten. The
ingestion of gluten proteins contained in wheat, barley, and rye,
and, in some cases, oats [6,7], leads to characteristic inflammation,
villous atrophy, and crypt hyperplasia in the CD patient upper
small intestine [2].
In wheat gluten, the principal toxic components belong to a
family of closely related proline and glutamine rich proteins called
gliadins [8]. Several epitopes responsible for the toxicity of gliadins
have been identified based on their ability to stimulate
proliferation of gluten-responsive DQ2 (or DQ8) restricted
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CD4+ T cells in CD patient-derived small intestine biopsies [9–
12]. To elicit a T-cell response, most gliadin epitopes must
undergo a transglutaminase 2-mediated deamidation of certain
glutamine residues to glutamate residues [10].
Among the main dietary proteins, gluten is unique in that it
contains approximately 15% proline and 35% glutamine residues
[13]. This high proline and glutamine content prevents complete
proteolysis by gastric and pancreatic enzymes, such that long
oligopeptides that are toxic to CD patients build up in the small
intestine. One peptide in particular, the 33-mer from a-2 gliadin
(residues 57–89), contains 6 T-cell epitopes, is highly proteolyti-
cally resistant, and is a principal contributor to gluten immuno-
toxicity [14]. It has been proposed that oral administration of a
therapeutic dose of a suitably formulated prolyl endopeptidase (SC
PEP from Sphingomonas capsulata) and glutamine specific endopro-
tease (EP-B2, a cysteine endoprotease from germinating barley
seeds) might counter the toxic effects of certain quantities of
ingested gluten [15–20].
At present, the prescription of a gluten-free diet is the only
therapy for CD patients. However, it is not easy to maintain a
diet with zero gluten content because gluten contamination in
food is commonplace [21]. Gluten is a common ingredient in the
human diet; after sugar, it is perhaps the second most widespread
food substance in Western civilization. Since about 10% of
gluten seems to be made up of potentially toxic gliadin peptides
[22], it is desirable to quantify the amount of these peptides
ingested by a CD patient, so that the factual toxicity of the gluten
present in foods can be established more precisely. In a previous
work, we obtained monoclonal antibodies (moAb) (G12 and A1)
against the gliadin 33-mer peptide [23]. The aims of the current
study were two-fold. First, we sought to characterize the
sequence specificity of these anti-33-mer moAbs using a panel
of overlapping fusion peptides based on the 33-mer sequence.
Second, we evaluated the practical efficacy of these moAbs as
analytical tools for quantifying food toxicity for CD patients.
Toward this end, we showed that the reactivity of each moAb
with a variety of cereal storage proteins correlated with the
immunotoxicity of those dietary grains from which the proteins
were extracted. Additionally, we showed with one of these moAb
(A1) that reductions in the 33-mer content of commercial whole-
wheat bread caused by treatment with candidate therapeutic
glutenases can be quantified using a simple, high-throughput
competitive ELISA. Our results establish A1 and G12 anti-33-
mer moAbs as specific and reliable tools for detecting foods
potentially harmful for CD patients.
Results
Detection of gliadin immunogenic peptide by anti-33-
mer moAbs
The 33-mer peptide from a-2 gliadin is a principal contributor
to gluten immunotoxicity [14]. Thus the production of moAbs
against this toxic gluten peptide could be of great importance in
both research and diagnosis. In a previous work, we obtained
moAbs against the 33-mer peptide (A1 and G12 moAbs) [23]. To
test the relative sensitivity of each moAb for the 33-mer peptide,
we immobilized different concentrations of the C-LYTAG-33-mer
polypeptide, and detected with A1 and G12 moAb in an indirect
ELISA. The affinity of each moAb for the antigen was quantified
by calculation of the concentration of the antigen giving a 50%
reduction of the peak signal in the ELISA (IC50). The sensitivity of
the G12 moAb for the toxic 33-mer peptide was about eight times
higher than that of A1 (Figure 1A). To test for moAb specificity,
we studied the cross-reactivity values (CR) of these moAb against
commercial gliadin, also by indirect ELISA. The G12 moAb
presented an IC50 of almost double that obtained with the A1
moAb, suggesting that A1 had broader reactivity with gliadin
epitopes than G12, which is more specific for the 33-mer
(Figure 1B).
Characterization of A1 and G12 moAbs sensitivity for
celiac-toxic cereals
In a previous work, we investigated whether the G12 moAb was
able to detect the presence of gliadin 33-mer related epitopes in
prolamins from various cereals [23]. The results indicated that the
moAb showed CR against prolamins of wheat, barley, rye and oats
Figure 1. Standard curve of the detection of C-LYTAG-33-mer polypeptide (A) and Sigma gliadin (B) by indirect ELISA with use of
moAbs G12 (black) and A1 (white). Each point of the curve represents the mean6standard deviation of n = 4 assays. IC50 values of the moAbs to
both antigens are indicated.
doi:10.1371/journal.pone.0002294.g001
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that are toxic for CD patients [23]. Since the A1 moAb showed
even higher sensitivity to wheat gliadin than G12, we evaluated the
reactivity of A1 moAb with other cereal grain prolamins. The
prolamins from wheat, barley, rye, oats, corn, and rice were
extracted, and the samples were analyzed by Western blot, using
the A1 moAb. The A1 moAb detected wheat gliadins, barley
hordeins, and rye secalins. Oat avenins were also detected by A1,
but the sensitivity obtained was lower (data not shown). The A1
moAb did not react to a detectable extent with prolamins
extracted from rice (oryzein) and corn (zein), cereals that are
non-toxic to CD patients.
To obtain quantitative data about the capacity of A1 to detect
celiac toxic prolamins, we performed an indirect ELISA with
samples of wheat, barley, rye, oats, rice, and corn (Figure 2). The
assay proved to be highly specific for wheat, rye and barley, as no
signal was observed in samples containing prolamins from rice or
corn (Figure 2). The G12 and A1 moAbs detected oats with lower
sensitivity, indicating that there are peptides in avenin with
sequence similarity to the 33-mer. This is consistent with the
identification of proline and glutamine rich epitopes in avenins
that are toxic in some CD patients [6]. The lower sensitivity for oat
avenins may be due to the lower proportion of oat flour protein
content that comprises prolamins relative to the proportion of
gliadins, hordeins or secalins in their respective grains [24].
The A1 moAb was clearly more sensitive than the G12 moAb
for the detection of the prolamin fractions from wheat, barley, rye,
and oats. Although they were targeted at the toxic 33-mer peptide
of wheat gliadin, both moAb were more sensitive for barley than
for wheat, and the A1 was also more sensitive for the prolamins of
rye than for those of wheat. Although both moAb were more
sensitive for barley than for wheat (Figure 2), the A1 moAb had
almost three-fold higher affinity for barley than did G12.
Development of a competitive ELISA assay using the A1
moAb
The preparation of many foodstuffs involves heating or
enzymatic processes that may partially hydrolyze or deamidate
gluten. As a result, the quantity of gluten extracted from foodstuffs
processed by heat or fermentation may be underestimated by
indirect or sandwich ELISA [25,26]. We therefore developed a
competitive ELISA in which the antigen was fixed on the plate
and soluble antigens in the sample, were preincubated with a HRP
conjugated moAb. Upon addition of this preincubated mixture to
the plate, soluble and fixed antigens competed for binding to the
HRP conjugated moAb. Thus, a decrease in the signal indicates
the presence of antigen in the sample. A competitive ELISA
method using G12 moAb was previously developed for detecting
toxic peptides in hydrolyzed food down to 0.5 ppm gliadin [23].
Here we developed a similar assay using the A1 moAb.
Several assays were carried out to optimize the conditions for
the competitive ELISA, including altering the concentration of
gliadin fixed on the plate (1–0.01 mg/well), the dilution of A1-
HRP moAb used (1:1,000–1:50,000), and the time (15 min to 4 h)
and temperature (4uC, room temperature, and 37uC) of
preincubation and incubation. A concentration of 0.5 mg/well of
gliadin fixed on the plate and a 1:10,000 dilution of the A1-HRP
moAb were found to be optimal (data not shown). A preincubation
of 3 h and an incubation of 40 min, both at room temperature,
were found to be optimal. The resulting highly sensitive
competitive assay had a limit of detection of 1.63 ng/mL of
gliadin (0.33 ppm of gluten) and a limit of quantification of
6.98 ng/mL of gliadin. IC50 in the standard curve of the
competitive assay was 15.76 ng/mL. The standard curve for the
detection of toxic gliadin by competitive ELISA under the
established conditions showed a good correlation to the data
(R2 = 0.99).
The repeatability and reproducibility of the method, calculated
from various standard curves performed on the same ELISA plate
(intra-assay), and on different ELISA plates (inter-assay), were
determined. The intra-assay coefficient of variation of the
standards situated between 100 and 1.56 ng/mL of gliadin was
found to be between 1.37% and 5.21%, while the inter-assay
coefficient of variation was between 3.16% and 11.78% for the
same standards.
Figure 2. Comparative reactivity of prolamins from wheat, barley, rye, oats, corn and rice from indirect ELISAs using moAbs G12
(black) and A1 (white). Each point of the curve shows the mean of n = 3 assays. IC50 and CR values of the moAbs to prolamins are indicated. N.A.:
Not applicable.
doi:10.1371/journal.pone.0002294.g002
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Analysis of the epitope recognition of G12 and A1 moAb
To determine the epitope recognized by the G12 and A1 moAb
within the 33-mer peptide, fusions of the C-LYTAG coding
sequence of the pALEXb plasmid (Biomedal S.L., Sevilla, Spain)
were constructed with coding sequences of hepta- and octapep-
tides comprising the complete sequence of the 33-mer peptide
(Figure 3A). The resulting plasmids were introduced by transfor-
mation into the REG1 strain of Escherichia coli, allowing for over-
expression of the encoded fusion proteins upon induction
(Biomedal S.L., Sevilla, Spain). The over-expressed bacterial
extracts were analyzed by indirect ELISA using the anti-33-mer
A1 and G12 moAbs. Similarly, the anti-C-LYTAG 6B5L1 moAb
(Biomedal, S.L., Sevilla, Spain) was used to establish that the
designed protein was expressed intact in all cases. A reference
signal in the bacterial extract containing the C-LYTAG-33-mer
fusion protein was observed for all the moAbs assayed (A1, G12
Figure 3. Analysis of anti-33-mer moAbs recognition regions in recombinant 33-mer peptide fragments expressed in E. coli. A.
Nucleotide sequences and the deduced amino acid sequences of the encoded peptide fusions to C-LYTAG. B. Detection of C-LYTAG-peptide fusions
by an indirect ELISA with the use of moAbs G12, A1 and 6B5L1.
doi:10.1371/journal.pone.0002294.g003
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and 6B5L1) (Figure 3B). Saturating signals were obtained in the
indirect ELISA analysis using the anti-C-LYTAG 6B5L1 moAb
for all the analyzed fusion proteins, indicating that all fusion
proteins were over-expressed (Figure 3B).
With regard to the determination of the sequence of recognition
of the anti-33-mer moAbs (G12 and A1), a positive signal was
detected only in the bacterial extracts containing the fusion
peptides Pro63-Tyr69 (PQPQLPY) and Gln64-Pro70 (QPQ-
LPYP) for the G12 moAb and in the bacterial extracts containing
the fusion peptide Gln66-Pro72 (QLPYPQP) for the A1 moAb
(Figure 3B). These results thus indicate that the region of
recognition within the 33-mer peptide for the G12 moAb is
QPQLPY (common to the fusion proteins Pro63-Tyr69 and
Gln64-Pro70) and that for the A1 moAb is QLPYPQP.
Study of the relative affinity of the G12 moAb for
different peptide variants derived from the regions of
recognition
The recognition sequence of the G12 moAb (QPQLPY) is
repeated three times within the gliadin 33-mer peptide. To
determine the relative affinity of G12 for this epitope, and for
similar sequences present elsewhere in toxic prolamins, we
constructed hexapeptide variants of the G12 epitope, two of
which were designed based on their presence in the prolamins of
barley and rye (Figure 4A and 4C). The affinity of the G12 moAb
for different hexapeptide variants was determined in a competitive
assay in which immobilized gliadin was challenged with
QPQLPY-derivative peptides as soluble competitors (Figure 4A).
The G12 moAb had high affinity for the peptide QPQLPF,
reduced only four-fold relative to the previously identified epitope
recognized by this moAb in the 33-mer, QPQLPY (Figure 4B).
While the conservative replacement of tyrosine (QPQLPY) with
phenylalanine (QPQLPF) did not drastically reduce the affinity of
the G12 moAb, substitution with leucine (QPQLPL) reduced the
affinity a thousand-fold, indicating the importance of this last
position in determining affinity. A dramatic reduction in affinity
was also observed for the peptide QPQQPY, such that the affinity
of the anti-33-mer G12 moAb decreased as follows:
QPQLPY.QPQLPF&QPQLPL.QPQQPY.
Determination of the peptide sequence preferences for
moAb A1 binding
We also studied the relative affinity of the A1 moAb for its
recognition sequence (QLPYPQP) and for related peptide variants
Figure 4. Relative affinity of moAb G12 for different peptide variants derived from its recognition region (QPQLPY). A. Amino acid
sequences of the peptides. The G12 recognition sequence in the 33-mer peptide is in bold face. IC50 and CR values of the moAb G12 to peptides are
indicated. B. Competition assay measuring the affinity of the moAb G12 for the peptides. Two separate assays were performed with the antibody,
each with three repetitions. C. Localization of the peptides in the a-gliadin (accession number: JQ1047), c-secalin (accession number: ABO32294.1)
and C-hordein (accession number: AAA92333.1) sequences. The same color code for labelling the peptides has been used in A, B and C.
doi:10.1371/journal.pone.0002294.g004
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by a competitive assay (Figure 5A). The peptides assayed for A1
were more numerous than for G12 due to the longer heptapeptide
recognition sequence recognition contained in the 33-mer and due
to the suspected broader specificity of A1 for other prolamin
sequences based on indirect ELISA assays (Figure 2). Figure 5
shows the affinity of the A1 moAb for the different peptides
assayed; the IC50 was used to compare the affinity of A1 for each
peptide. Notably, two peptides present in secalin and hordein
(QQPFPQP and QLPFPQP, Figures 5C and 5D, respectively)
showed higher affinity for the A1 moAb than did the 33-mer-
derived recognition sequence peptide (QLPYPQP). This suggests
that the fourth residue in the recognition sequence is substantially
important to A1 recognition, whereas the second position is not.
Consistent with this, gliadin peptides QLPYPQP and QQPYPQP
showed comparable affinity for the moAb (Figure 5B). The affinity of
the anti-33-mer A1 moAb for epitopes present in celiac-toxic ce-
reals decreased as follows: QLPFPQP.QQPFPQP.QLPYPQP.
QQPYPQP&QQPYPQE.
The affinity for the sequence included in the wheat gliadin 33-
mer was not as high as for QQPFPQP, which is one of the most
abundant sequences in secalin and hordein, similar to the 33-mer
epitope in gliadin. This may explain why, despite its lower affinity
for 33-mer peptide relative to the G12 moAb, the A1 moAb had
higher sensitivity for the whole range of toxic cereals tested in this
study. The A1 moAb may therefore be useful as a sensitive
detection tool for identifying celiac-toxic peptides in complex
foodstuffs.
Preliminary attempts to find an avenin epitope gave no positive
results (Figure 5E). The prolamins in oats represent much less of
the total seed proteins than in the other cereals [24]. Furthermore,
the amount of proline residues contained in avenins (10%) is about
two-thirds that in the prolamins of wheat (gliadins and glutenins),
barley (hordeins), and rye (secalins). In any case, we tested certain
previously proposed potential avenin epitopes located in the
avenin regions with the highest content of proline residues, regions
also rich in glutamine, but could not obtain any reactivity to the
A1 moAb.
To study the relative importance of glutamine and proline
residues in epitope selection by the A1 moAb, single substitutions
or deletions were made to these amino acids in the recognition
sequence (QLPYPQP; Figure 6A). We performed the analysis with
the A1 moAb rather than with the G12 moAb because A1 has
higher sensitivity for prolamins from toxic cereals. When the first
glutamine of the A1 recognition sequence was eliminated
(LPYPQP), the affinity for A1 decreased significantly, consistent
with the results from epitope scanning with the C-LYTAG fusions
(Figure 3). Substitutions of each proline residue in the recognition
sequence with a serine residue decreased A1 affinity markedly
(Figures 6A and 6B). This effect was most marked when the
substitution was made in the second proline position (QLPYSQP),
resulting in a CR that was practically zero.
These results indicate that the initial glutamine residue and all
three prolines of the epitope QLPYPQP were important for its
recognition by A1, suggesting that this moAb could serve as a tool
for monitoring enzymatic degradation of toxic peptides by
potentially therapeutic glutamine and proline specific proteases.
Use of moAb A1 to monitor gluten detoxification by
candidate glutenases
Oral administration of glutamine and proline specific proteases
(i.e. glutenases) represents a potential therapeutic alternative (or
adjunct) to a gluten-free diet [27,28]. However, validation of the
efficacy of these enzymes at detoxifying gluten in vitro must precede
clinical testing, and such validation currently relies on low-
throughput, technically challenging cell culture-based assays
[19,20,27] or on polyclonal anti-gliadin antibody-based ELISA
assays that are only grossly quantitative [20]. A competitive ELISA
using a anti-33-mer moAb would enable high-throughput, highly
quantitative testing of gluten detoxification by candidate thera-
peutic glutenases.
We digested commercial whole-wheat bread under mock gastric
conditions for 60 min with pepsin supplemented either with EP-B2
at varied concentrations (Figure 7A), or with a fixed EP-B2
concentration plus varied concentrations of SC PEP (Figure 7B).
Dilution series of the quenched digests were prepared in parallel
with a calibration dilution series of chemically synthesized 33-mer
peptide, and these were tested against fixed 33-mer in an indirect
competitive ELISA using moAb A1. Treatment of whole-wheat
bread with EP-B2 reduces the concentration of the 33-mer and
close analogs by up to 10-fold in a dose-dependent manner
(Figure 7A). This is consistent with the observation that EP-B2
cleaves the 33-mer after Gln66, Gln73, and Gln80 [17], cleavages
expected to extirpate the affinity of A1 for the resultant fragments
(Figures 3 and 6). The combination of EP-B2+SC PEP further
reduced antigen concentrations by at least an additional 10-fold to
levels undetectable by our methods (Figure 7B). This is again
consistent with previously published results, in which EP-B2
substantially detoxified similar bread digests, but the synergistic
combination of EP-B2 with SC PEP was required to dramatically
reduce the intestinal T cell reactivity of these digests [20]. The
intensity of the signal obtained with the A1 moAb in our assay was
therefore proportional to the potential damage caused to a CD
patient by a commercial gluten source.
Analysis of the recognition of anti-33-mer moAbs for
deamidated and innate gluten peptides
CD is closely associated with genes that code for human
leukocyte antigens DQ2 and DQ8. These have been shown to
bind with high affinity to gliadin-derived peptides in which specific
glutamine residues in key positions have been converted to
glutamic acid by transglutaminase 2-mediated deamidation [1,16].
A moAb capable of discriminating between native and deamidated
gluten peptides would be a valuable research tool for monitoring
the fate of digested prolamin peptides. To test the relative
sensitivity of each moAb for the deamidated 33-mer peptide, a
peptide (QPQLPYPQP) was designed that represented a region of
recognition common to the two moAbs, together with the same
peptide deamidated (QPELPYPQP) (Figure 8A). The affinities of
the A1 and G12 moAbs for these peptides were determined by a
competitive assay in which immobilized gliadin was challenged
with peptides as competitors. The affinity of the G12 moAb for the
deamidated peptide was about forty times higher than that of the
A1 moAb (Figure 8A). However, both moAbs recognized the non-
deamidated peptide with .100-fold greater affinity than they did
the deamidated peptide (Figure 8A). In combination with a
previously characterized, commercially available moAb that has
20-fold greater affinity for the deamidated form of an overlapping
gluten peptide than for its non-deamidated counterpart [29],
moAbs G12 and A1 may be useful for future studies on
transglutaminase 2-mediated gluten peptide deamidation.
The innate immune response to gluten plays a key role in the
development of CD [30,31]. This response is mediated by
interleukin 15 (a typical cytokine of the innate immune system)
and elicited by the toxic peptide, p31-49 (19-mer), derived from
alpha-gliadin [31]. To test whether the anti-33-mer A1 and G12
moAbs recognized peptide p31-49, competitive ELISAs with each
moAb were performed. The A1 moAb was able to detect p31-49
(IC50 3.18 mg/mL) (Figure 8B). The G12 moAb showed no
MoAbs to Toxic Gluten Peptides
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Figure 5. Relative affinity of moAb A1 for different peptide variants derived from its recognition region (QLPYPQP). A. Amino acid
sequences of the peptides. The A1 recognition sequence in the 33-mer peptide is in red. B, C, D and E. Competition assay for detection of the affinity
of the moAb A1 for the peptides and their localization in a-gliadin (B; accession number: JQ1047), c-secalin (C; accession number: ABO32294.1), C-
hordein (D; accession number: AAA92333.1) and avenin (E; accession number: AAA32716.1). Two separate assays were performed with the moAb,
each with three repetitions. IC50 values of the moAb A1 to peptides are indicated. N.A.: Not applicable. The color code for labelling the peptides is
the same as that used in A.
doi:10.1371/journal.pone.0002294.g005
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affinity for the 19-mer peptide (Figure 8B). These results were
consistent with our previous identification of the QQPYPQP
peptide, included in p31-49, as a permissive epitope for the A1
moAb (Figure 5B). Therefore, this moAb shows an interesting
range of peptide recognition that includes gliadin peptides
involved in the both the adaptive and innate immunological
responses in CD.
Discussion
In this work, we characterized two moAbs raised against the
immunotoxic gliadin 33-mer peptide, each of which showed
suitable epitope recognition for fundamental and practical
applications in CD research. The most straightforward of these
is that these moAbs may be used to detect immunotoxic gluten
epitopes in foodstuffs via immunological assays. In a previous work
we obtained moAbs (G12 and A1) against the 33-mer, a peptide
from a-2 gliadin that is a principal contributor to gluten
immunotoxicity [14]. Here, we characterized the precise site of
peptide recognition and the practical efficacy of these moAbs as
analytical tools for quantifying food toxicity for CD patients.
ELISAs based on moAbs G12 and A1 exhibited broad specificity
toward prolamins toxic to CD patients, along with a high degree of
sensitivity, accuracy, and reproducibility. The A1 moAb was
particularly sensitive to immunotoxic prolamins, with highest
affinity for barley and rye, followed by wheat. The G12 moAb was
more specific for the 33-mer than was A1, but it also recognized all
immunotoxic prolamins, with highest affinity for barley and wheat,
followed by rye. Both moAbs detected oat prolamins, albeit with
substantially reduced sensitivity. To provide a basis for these
observed sensitivities, we identified the hexapeptide (QPQLPY)
and heptapeptide (QLPYPQP) epitopes recognized by G12 and
A1 moAbs, respectively, and studied the relative affinity of these
moAbs for peptide variants of their recognition sequence. This
analysis suggested that A1 showed higher affinity for prolamins of
wheat, barley, rye and oats than did G12 as a consequence of the
prevalence of the A1 recognition sequence and related sequences
in these cereals.
The ability of G12 and A1 to detect oats is of potential practical
importance. Oats cause damage to the mucosa in a subset of CD
patients [2,6]. In contrast to previously described anti-prolamin
moAbs (e.g. R5 and anti-glia-a2/9) [32,33], G12 and A1 both
detected oats although with lower sensitivity than the prolamins
from wheat, barley and rye. Peptides recognized by these moAbs
were confirmed by western blot (data not shown), exhibiting a
pattern not indicative of contamination by other cereals. The
reduction in G12 and A1 sensitivity toward oat prolamins relative
to immunotoxic prolamins from wheat, rye, and barley may be
due to the lower prolamin content in total oat seed protein
compared to the other cereals [24]. Moreover, the potential
sequences for moAb recognition could be less prevalent in avenins
than in gliadins, hordeins, and secalins. Regardless, ELISA assays
using G12 and A1 exhibited high sensitivity toward toxic wheat,
rye, and barley prolamins; reduced but significant sensitivity
toward oat prolamins, which are moderately toxic in a subset of
CD patients; and no sensitivity toward non-toxic prolamins from
corn and rice. Together, these observations reveal a direct
correlation between assay signal and potential toxicity of food
samples for CD patients.
This correlation suggested that an ELISA using a moAb specific
for immunotoxic gluten epitopes could be used to quantitatively
monitor the enzymatic detoxification of gluten. The use of
glutamine and proline specific proteases (EP-B2 and SC PEP,
respectively) is currently being explored as an oral therapy for CD
[15–20]. Because our results suggested that the initial glutamine
residue and all three prolines in the recognition sequence for A1
were substantially important for A1 recognition, we used this
moAb to determine the concentration of immunotoxic epitopes
remaining in wheat bread after its treatment with varying amounts
of EP-B2 and SC PEP. Decreases in A1 epitopes due to enzymatic
digestion by glutenases were consistent with previously reported
decreases in T cell activation caused by identical enzymatic
treatment of wheat bread [20]. Therefore, the A1 moAb
immunoassay may be used to monitor gluten detoxification in
enzymatic therapy studies by detecting that part of the digested
food that remains toxic for a CD patient.
The 33-mer gliadin peptide and other main prolamin epitopes
are deamidated at specific glutamine residues by transglutaminase
2, considerably enhancing their affinity for HLA DQ2 or DQ8
molecules [10,12]. This transformation is suggested to be critical
toward rendering gluten immunotoxic. We determined the
affinities of G12 and A1 moAbs for a synthetically deamidated
gluten peptide, and found that both moAbs recognized the
deamidated peptide with .100-fold less affinity than they did the
Figure 6. Relative affinity of moAb A1 for peptide variants of
the 33-mer recognition region (QLPYPQP) featuring single
amino acid sustitutions. A. Amino acid sequences of the peptides.
The A1 recognition sequence in the 33-mer peptide is in bold face. IC50
and CR values of the moAb A1 to peptides are indicated. B.
Competition assay for the detection of the affinity of the moAb A1
for the peptides. Two separate assays were performed with the
antibody, each with three repetitions. The color code for labelling the
peptides is the same as that used in A.
doi:10.1371/journal.pone.0002294.g006
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Figure 7. Indirect competitive ELISA using moAb A1 to test whole-wheat bread digests for 33-mer content. A. Concentration of 33-mer
(mg/mL) in whole-wheat bread digests containing 0.6 mg/mL pepsin supplemented with specified concentrations of recombinant proEP-B2 (U/mg
gluten). B. Concentration of 33-mer (mg/mL) in whole-wheat bread digests containing 0.6 mg/mL pepsin and 32 U/mg EP-B2 supplemented with
specified concentrations of recombinant SC PEP (U/mg gluten). The concentration of 33-mer in each digest was determined by comparison to a
synthetic 33-mer standard curve. Two separate assays were performed with the antibody, each with three repetitions.
doi:10.1371/journal.pone.0002294.g007
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non-deamidated peptide. These moAbs may be useful for
fundamental studies on the mechanism of transglutaminase 2
mediated deamidation either in vitro or in vivo by discriminating
between native and deamidated gluten peptides. Additionally,
these moAbs may be used to test the extent to which microbial
transglutaminase treatment can abolish gluten toxicity by blocking
immunotoxic peptide deamidation sites [34].
Finally, we reported the development of a novel competitive assay
using A1, a moAb raised against a 33-mer peptide recognized in vivo
to be immunotoxic toward patients with CD. A competitive assay is
well-suited for food analysis and monitoring of gluten digestion
because it can detect both intact proteins and small protein
fragments, the latter of which can be underestimated by a sandwich
ELISA [32,35]. The ELISA systems described here showed high
reproducibility and repeatability with coefficients of variation below
15%. Taking the minimum working dilution as 1:10, and starting
from a sample (obtained by ethanolic (60%) extraction from a
foodstuff) at a concentration of 0.1 g/mL of extraction solution, the
A1 competitive ELISA developed would enable the detection of the
presence of gluten in foodstuffs at values as low as 0.33 ppm of
gluten, which is far below the 20 ppm threshold proposed by the
Codex Alimentarius Commission [36]. The recommended maxi-
mum daily ingestion of gluten is below 50 mg gluten per day. The
method reported here could detect several orders of magnitude less
concentration than the maximum recommended gluten concentra-
tion in the digestive tract (,20 mg/L) for CD patients [37]. The
specificity for immunotoxic peptides obtained by developing moAbs
G12 and A1 against the immunotoxic 33-mer is an additional
advantage of this immunoassay, since anti-gliadin moAbs with no
specificity for toxic peptides may produce false negative or positive
signals not related to the remaining toxicity of hydrolyzed food. This
work suggests that competitive immunoassays using immunotoxic
gluten epitope-specific moAbs, such as G12 and A1, are particularly
effective at evaluating food safety for CD patients, with likely
advantages over assays measuring the amount of any gluten in a
given sample, without regard to its immunotoxicity.
Materials and Methods
Materials
Commercially available flours from cultivars of wheat, barley,
rye, oats, corn, and rice were employed in this study.
The peptides QPQLPYPQP, QPELPYPQP, QPQLPY,
QPQLPF, QPQLPL, QPQQPY, QLPYPQP, QQPYPQP,
QQPFPQP, QQPYPQE, QLPFPQP, QQPFVQQ, QQMFLQP,
QLPYPQS, QLSYPQP, QLPYSQP and LPYPQP were supplied
by Biomedal S.L. (Sevilla, Spain). The 19-mer peptide
PGQQQPFPPQQPYPQPQPF was provided by Eduardo Arranz
(Universidad de Valladolid-C.S.I.C., Valladolid, Spain).
Whole-wheat bread (Alvarado St Sprouted Whole-Wheat
Bread) was from Alvarado St Bakery (Rohnert Park, CA). The
Figure 8. Relative affinity of the anti-33-mer moAbs for
different peptides involved in the immune responses to gluten
in CD patients. A. Competition assay for detection of the affinity of
G12 and A1 moAbs for a peptide containing recognition common
regions (QPQLPYPQP) to the two moAbs and its deamidated
counterpart (QPELPYPQP). IC50 and CR values of the anti-33-mer
moAbs to peptides are indicated. B. Competition assay for detection of
the affinity of the moAbs G12 and A1 for the innate peptide, p31-49.
The 33-mer and the p31-49 peptide sequences are underlined and in
bold face, respectively. Wheat alpha-gliadin (a-gliadin, accession
number: JQ1047). Two separate assays were performed with the
antibodies, each with three repetitions (A and B).
doi:10.1371/journal.pone.0002294.g008
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synthetic 33-mer peptide used to calibrate the competitive ELISA
on bread digests was synthesized using Boc/HBTU chemistry on
solid-phase as previously described [38]. Pepsin was purchased
from American Laboratories (Omaha, NE). EP-B2 and SC PEP
were prepared as previously described [15,17,39]. Enzyme stock
concentrations and specific activities are the same as previously
reported [20].
Anti-33-mer moAbs
The A1 moAb, G12 moAb and their derived Horseradish
Peroxidase (HRP)-conjugated moAb (A1-HRP and G12-HRP)
were used in this study [23]. A1, G12 and A1-HRP moAb
concentrations are 3.6 mg/mL, 1 mg/mL and 0.6 mg/mL,
respectively. G12-HRP moAb concentration is the same as
previously reported [23].
Determination of the moAbs A1 and G12 recognition
sequence within the 33-mer peptide
In order to determine the A1 and G12 recognition sequence,
several fragments of DNA codifying for peptides representing the
whole 33-mer sequence were constructed by synthesis of the
following overlapping oligonucleotides: Leu57-Pro63, 59-
GATCTGCAGTTACAACCGTTTCCGTA-39, and 59-AGCT-
TACGGAAACGGTTGTAACTGCA-39; Pro63-Tyr69, 59-
GATCCGCAGCCACAACTGCCGTATTA-39, and 59-AGCT-
TAATACGGCAGTTGTGGCTGCG-39; Gln64-Pro70, 59-
GATCAGCCACAACTGCCGTATCCGTA-39, and 59- AGCT-
TACGGATACGGCAGTTGTGGCT-39; Pro65-Gln71, 59-
GATCCACAACTGCCGTATCCGCAATA-39, and 59- AGCT-
TATTGCGGATACGGCAGTTGTG-39; Gln66-Pro72, 59-
GATCAACTGCCGTATCCGCAACCATA-39, and 59-AGCT-
TATGGTTGCGGATACGGCAGTT-39; Leu67-Gln73, 59-
GATCTGCCGTATCCGCAACCACAGTA-39, and 59-AGCT-
TATTATGGTTGCGGATACGGCA-39; Pro68-Leu74, 59-
GATCCGTATCCGCAACCACAGTTGTA-39, and 59-AGCT-
TACAATTATGGTTGCGGATACG-39; Pro82-Phe89, 59-
GATCCGTATCCTCAACCGCAACCGTTTTA-39, and 59-
TAAAACGGTTGCGGTTGAGGATACG-39. These synthetic
DNAs were designed according to the typical codon usage of E. coli
to maximize the expression. The resultant synthetic DNA
fragments were assembled by hybridization, and cloned into the
BamHI-HindIII digested pALEXb plasmid (Biomedal S.L., Sevilla,
Spain). This plasmid contained the Pm promoter of the Cascade
expression system [40,41] and the C-LYTAG for affinity
purification of fusion peptides to a choline binding domain
(Biomedal S.L., Sevilla, Spain). The resultant pALEXb-derivative
plasmids were checked by sequencing, and transformed into the
Cascade expression host E. coli REG1 (Biomedal S.L., Sevilla,
Spain). A plasmid for the expression of a C-LYTAG-33mer fusion
was constructed in a previous work [23] and used in this study as
positive control. Cultures were then induced by addition of 2 mM
salicylate and incubated 5 h at 30uC. The soluble protein extracts
were used for the determination of the A1 and G12 recognition
sequence by indirect ELISA.
Preparation of gliadin solution
Gliadin (Sigma, St. Louis, Missouri, U.S.A.) was prepared in
60% (v/v) aqueous ethanol at 1 mg/mL.
Preparation of prolamins from wheat, barley, rye, oat,
corn, and rice flours
Prolamins from wheat, barley, rye, oat, corn, and rice flours
were extracted by mixing 0.5 g of flour with 5 mL 60% (v/v)
ethanol in a rotary shaker for 1 h at room temperature. The
suspension was then centrifuged at 2,500 g for 10 min; the
supernatant was separated, and protein concentration was
measured by the Bradford method. The required concentration
of these samples was prepared in 0.02 M PB containing BSA
(5 mg/mL) before use in immunoassays.
Indirect enzyme-linked immunosorbent assay
A Maxisorp microtiter plate (Nunc, Roskilde, Denmark) was
coated overnight at 4uC with 100 mL/well of the appropriate
antigen (C-LYTAG-33-mer protein, gliadin, hordein, secalin,
avenin, oryzein, zein or soluble protein extracts containing
peptide fusions) serially diluted with 0.1 M of Na2CO3-NaHCO3
(pH 9.6). After washing with PBS containing 0.05% Tween-20
(washing buffer), 300 mL of blocking buffer (washing buffer
supplemented with 5% non-fat dry milk) was added to each well,
and incubated for 1 h at room temperature. Plates were incubated
for 1 h at room temperature with the G12 moAb (1:1,000 in the
blocking solution), A1 moAb (1:500 in the blocking solution) or
6B5L1 moAb (1:1,000 in the blocking solution). After washing,
goat anti-mouse IgG-peroxidase antibody (Biomedal S.L., Sevilla,
Spain) was added (1:2,000 in the blocking solution). Plates were
washed again, and the substrate solution (TMB liquid substrate
system, Sigma, St. Louis, Missouri, U.S.A.) was added. After
30 min dark incubation, the reaction was stopped with 1 M
sulfuric acid. Absorbance at 450 nm was measured in the
microplate reader UVM340 (Asys Hitech GmbH, Eugendorf,
Austria).
Competitive enzyme-linked immunosorbent assay
G12 competitive ELISA was carried out according to Moro´n et
al. [23]. For the A1 competitive ELISA, Maxisorp microtiter
plates (Nunc, Roskilde, Denmark) were coated with 100 mL/well
of Sigma gliadin solution (5 mg/mL) in 0.1 M of Na2CO3-
NaHCO3 (pH 9.6), and incubated overnight at 4uC. Plates were
washed with washing buffer and blocked with blocking solution for
1 h at room temperature. Gliadin and samples serially diluted in
PBS containing 3% BSA (100 mL) and 100 mL solution of A1
moAb conjugated to HRP (1:10,000 in PBS containing 3% BSA)
were preincubated 3 h at room temperature with gentle mixing,
and then added to the wells. After 40 min incubation at room
temperature, the plates were washed, and 100 mL per well of
substrate solution (TMB liquid substrate system, Sigma, St. Louis,
Missouri, U.S.A.) was added. After dark incubation for 30 min at
room temperature, color development was stopped with 1 M
sulfuric acid (100 mL per well), and the absorbance was measured
at 450 nm (microplate reader UVM340, Asys Hitech GmbH,
Eugendorf, Austria).
Western blot reactivity of the A1 moAb
For the Western blot of cereal extracts, after one-dimensional
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), proteins were electrotransferred on to polyvinylidene
difluoride (PVDF) membranes, incubated directly with A1-HRP
moAb, and developed by ECL Western Blotting Analysis System
immunodetection (Amersham Biosciences, Little Chalfont, Buck-
inghamshire, U.K.).
Whole-wheat bread digests and indirect competitive
ELISA for 33-mer in digests
Whole-wheat bread digests were carried out as previously
described [20]. Briefly, whole-wheat bread (1 g) presoaked in
specified amounts of EP-B2 and SC PEP (units of activity/mg
MoAbs to Toxic Gluten Peptides
PLoS ONE | www.plosone.org 11 May 2008 | Volume 3 | Issue 5 | e2294
gluten protein) was added to a 37uC 0.01N HCl solution
containing 0.6 mg/mL pepsin over a course of 15 min, resulting
in a final pH of ,4.5 and a final measured gluten protein
concentration of ,15 mg/mL. After this addition phase, the
simultated gastric digests were incubated for 60 min at 37uC,
quenched by boiling 5 min, and stored at 220uC.
The concentration of 33-mer or related epitopes remaining in
each digest was determined by an indirect competitive ELISA
using moAb A1. On day 1 of the procedure, synthetic 33-mer was
diluted to 1.6 mg/mL in coating solution (50 mM sodium
carbonate/bicarbonate buffer, pH 9.6, 0.02% NaN3) and
100 mL/well was incubated overnight at 4uC in 96-well microtiter
plates (Nunc Maxisorp). Synthetic 33-mer standards (0.00625–
51.2 mg/mL) or bread digest dilutions (1:10–1:163,840) were
prepared in StartingBlock T20 (TBS) blocking buffer (Pierce). An
equal volume of A1 moAb diluted 1:5,000 in blocking buffer was
added to each standard or sample dilution, and these mixtures
were incubated overnight at 4uC. Final dilutions in mixtures were:
1:10,000 A1 moAb and either 0.003125–25.6 mg/mL 33-mer
standards or 1:20–1:327,680 digest dilutions. On day 2, antigen-
coated plates were washed thrice with washing buffer prior to
blocking and between all subsequent steps. Plates were blocked
with 200 mL/well blocking buffer for 1 h at room temperature.
MoAb/standard and moAb/sample preincubations were added to
the wells in triplicate (100 mL/well) and incubated 3 h at room
temperature. Goat anti-mouse IgG-alkaline phosphatase conjugate
(Chemicon) was diluted 1:1,000 in blocking buffer and 200 mL/
well was incubated 3 h at room temperature. Freshly prepared
substrate solution (5 mg/mL pNPP, 50 mM sodium carbonate/
bicarbonate buffer, pH 9.8, 1mM MgCl2, 0.02% NaN3) was
added (200 mL/well) and the absorbance at 405 nm was measured
every 6 seconds for 5 minutes. The initial rate (mA405/min) of p-
nitrophenolate production in each well was determined from 31
datapoints. For each digest, the initial rates were plotted against
the log10 of the corresponding digest dilutions, yielding a sigmoidal
curve; the standard curve was similarly processed. The concen-
tration of 33-mer in each digest was determined from those digest
dilutions yielding initial rates within the linear region of the 33-
mer standard curve. As performed (i.e. at a minimal digest dilution
of 1:20), our assay’s lower limit of quantitation 15.3 mg/mL 33-
mer in the digest.
Statistical analysis
Peptide and prolamin curves were obtained by plotting
percentage of maximum absorbance against logarithm of antigen
concentration. The software package Sigma Plot 9.0 (Systat
Software, Inc., Point Richmond, CA, U.S.A.) was used to calculate
the IC50. The limit of detection was defined here as reagent blank-
3x standard deviations of reagent blank. The limit of quantifica-
tion was defined here as reagent blank-10x standard deviations of
reagent blank.
The CR was calculated as follows: (IC50 of the antigen for
which the moAb was raised/IC50 of each antigen assayed)X100.
The reproducibility (inter-plate variability) was assessed by
measuring the standard curve for different gliadin samples on two
separate ELISA plates on different days. The reproducibility
(intra-plate variability) was calculated by measuring the standard
curve eight times for the same gliadin sample on a single ELISA
plate. The coefficient of variation was calculated as follows:
standard deviation/mean6100.
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